Table 1.
Characteristics of serious cases reported with ivermectin as single suspect.
| Characteristics | Reported cases (n = 35) |
|---|---|
| Sex ratio (M/F) | 1.5 |
| Age (median [minimum, maximum]) | 51 [13,79] |
| Reporting region (n, %) | |
| North America | 13 (37.1%) |
| Europe | 9 (25.7%) |
| Asia | 7 (20.0%) |
| Latin America | 6 (17.1%) |
| Seriousness criterion (n, %)a | |
| Death | 6 (17.1%) |
| Life threatening | 9 (25.7%) |
| Disabling/incapacitating | 2 (5.7%) |
| Hospitalization | 16 (45.7%) |
| Other important condition | 18 (51.4%) |
| System organ class [SOC] (n, %) b | |
| Nervous system disorders | 10 (28.6%) |
| Injury, poisoning, procedural complications | 9 (25.7%) |
| General disorders and administration site conditions | 8 (22.9%) |
| Investigations | 7 (20.0%) |
| Gastrointestinal disorders | 7 (20.0%) |
| Respiratory, thoracic, mediastinal disorders | 7 (10.4%) |
| Infections and infestations | 6 (17.1%) |
| Skin and subcutaneous tissue disorders | 4 (11.4%) |
| Psychiatric disorders | 4 (11.4%) |
| Metabolism and nutrition disorders | 3 (8.6%) |
| Cardiac disorders | 3 (8.6%) |
| Eye disorders | 2 (5.7%) |
| Ear and labyrinth disorders | 2 (5.7%) |
| Musculoskeletal, connectives tissues disorders | 2 (5.7%) |
| Vascular disorders | 1 (2.9%) |
| Social circumstances | 1 (2.9%) |
a
Each case can correspond to multiple seriousness criteria.
b
Each case can correspond to 1 or more SOCs.